50 results on '"Di Maggio, Rosario"'
Search Results
2. β-Thalassemia heterozygote state detrimentally affects health expectation
3. Bone Marrow Transplantation in Nonmalignant Haematological Diseases: What Have We Learned about Thalassemia?
4. Reply to “Hepatocellular carcinoma in thalassemia and other hemoglobinopathies”
5. Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021
6. Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial
7. A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation
8. Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET
9. The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major
10. The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?
11. Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021.
12. Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy
13. Hemoglobinopathies and Cancer: Preliminary Results of an Italian Multicenter Experience
14. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial
15. An unknown cause of aortic valve stenosis: polycythemia vera
16. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
17. Development of a Severity Score System for Thalassemia Syndromes
18. LIC-R2 Values Predict Severity of SCD: Baseline Data from Licnet-S
19. Long‐term sequential deferiprone and deferasirox therapy in transfusion‐dependent thalassaemia patients: a prospective clinical trial
20. Sickle related events following cardiac catheterisation: risk implication for other invasive procedures
21. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
22. Inadequacy of Ferritin Trends for Predicting Changes in LIC Risk Category in Transfusion Depedent and Well Chelated Patients with Haemoglobinopathies
23. Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET
24. Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures
25. The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?
26. Comment on 'deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial'
27. Luspatercept in the Treatment of Beta Thalassemia in Italy: Lights and Shadows in Clinical Practice
28. Overcoming the Cost Barrier for Thalassemia Innovative Treatments
29. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET
30. Hematopoietic Stem Cell Mobilization for Gene Therapy: The Combination of G-CSF+Plerixafor in Patients with Beta-Thalassemia Major Provides High Yields of CD34+ Cells with Primitive Signatures
31. Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies
32. Survival Comparability Between Thalassemia Major Versus Thalassemia Intermedia
33. Wharton's Jelly- MSC As Effective Tool for Expansion of Purified Human Cord Blood CD34+ Hematopoietic Stem Cells
34. Mesenchymal Fetal Stem Cells (FMSC) from Amniotic Fluid (AF): Expansion and Phenotypic Characterization
35. Congenital Dyserythropoietic Anemias: Molecular Diagnosis and Diagnostic Approach in a Cohort of Italian Patients
36. Earlier Antenatal Diagnosis of Hemoglobinopathies By Coelocentesis
37. The Challenge of Using CB-HSCs As Source for Gene Therapy: Lentiviral Vector Transduction, Phenotypic Characterization and Global Gene Expression Profile of Ex-Vivo Expanded CB CD34+ Cells
38. Study on the Efficacy of a JAK Inhibitor Pharmacological Agent As Inducer of Fetal Hemoglobin Production in Cultured Erythroid Precursors from Sickle Cell and Beta-Thalassemia Patients
39. The Sea Urchin sns5 Chromatin Insulator Improves the Likelihood of Lentiviral Vectors in Erythroid Milieu By Organizing an Independent Chromatin Domain at the Integration Site
40. Chronic Administration of Hydroxyurea (HU) and Outcomes in Patients with Sickle Cell Disease (SCD) at a Single Referral Institution
41. Nonmyeloablative Hematopoietic Stem Cell Transplantation Improves a Marker of Diastolic Dysfunction in Patients with Sickle Cell Disease
42. Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi-Center Randomized Clinical Trial
43. Sickle related events following cardiac catheterisation: risk implication for other invasive procedures.
44. An unknown cause of aortic valve stenosis: polycythemia vera
45. Polycythemia Vera as a Predisposing Factor for Aortic Stenosis: Prevalence and Correlation with Blood Cells Count and Mutational Status
46. The Sea Urchin sns5Chromatin Insulator Improves the Likelihood of Lentiviral Vectors in Erythroid Milieu By Organizing an Independent Chromatin Domain at the Integration Site
47. A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation
48. Reply to 'Hepatocellular carcinoma in thalassemia and other hemoglobinopathies'
49. Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy
50. β-Thalassemia heterozygote state detrimentally affects health expectation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.